Complete if Known Substitute for form 1449A/PTO (Modified) 10/693,252 Application Number **CINFORMATION DISCLOSURE** Filing Date October 24, 2003 STATEMENT BY APPLICANT First Named Inventor Meade et al. / 1616 Art Unit (use as many sheets as necessary) To Be Assigned Examiner Name 6 Attorney Docket Number A-68448-3 1 of

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A1	3,919,102	11-11-1975	Kühling et al.				
	A2	4,637,988	01-20-1987	Hinshaw et al.				
	A3	4,647,447	03-01-1987	Gries et al.				
	A4	4,678,667	07-07-1987	Meares et al.				
	A5	4,822,594	04-18-1989	Gibby				
	A6	4,837,169	06-06-1989	Toner				
	A7	4,877,872	10-31-1989	Morgan et al.				
	A8	4,885,363	12-05-1989	Tweedle et al.				
	A9	5,087,440	02-11-1992	Cacheris et al.				
	A10	5,095,099	03-10-1992	Parkinson et al.				
	A11	5,133,956	07-28-1992	Gartich et al.				
-	A12 *	5,135,737	08-04-1992	Keana				
	A13	5,155,215	10-13-1992	Ranney				
	A14	5,188,816	02-23-1993	Sherry et al.				
	A15	5,219,553	06-15-1993	Kraft et al.				
	A16	5,230,883	07-27-1993	Kornguth et al.				
	A17	5,256,395	10-26-1993	Barbet et al.				
	A18	5,262,532	11-16-1993	Tweedle et al.				
	A19	5,292,414	03-08-1994	Sessier et al.				
	A20	5,310,539	05-10-1994	Williams				
	A21	5,322,681	06-21-1994	Klaveness				
	A22	5,332,567	07-26-1994	Goldenberg				
	A23 *	5,338,532	08-16-1994	Tomalia et al.				
	A24	5,358,704	10-25-1994	Desreux et al.				
	A25	5,358,705	10-25-1994	Boggs et al.				
	A26	5,407,657	04-18-1995	Unger et al.				
	A27	5,419,893	05-30-1995	Berg et al.				
	A28 *	5,428,154	06-27-1995	Gansow et al.				
·	A29	5,428,156	06-27-1995	Mease et al.				
	A30	5,446,145	08-29-1995	Love et al.				
	A31	5,466,438	11-14-1995	Unger et al.				

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

This collection of the patent document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English Language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the INSECO to precess) as application.

Confidentially operated by 35 CFR 1.97 and 1.98. The information is required to take 2 hours to complete.

USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1	Substitute for		A/PTO		Complete if Known			
	(M	lodified)		Application Number	10/693,252			
1	INFORMATIO			Filing Date	October 24, 2003			
1	STATEMENT BY APPLICANT			First Named Inventor	Meade et al.			
	2 2004			Art Unit	1616			
٩	(use as many sheets as necessary)			Examiner Name	To Be Assigned			
	Sheet 2	of	6	Attorney Docket Number	A-68448-3			

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A32	5,466,439	11-14-1995	Gibby et al.				
	A33	5,531,978	07-02-1996	Berg et al.				
	A34	5,554,748	09-10-1996	Sieving et al.				
	A35	5,565,552	10-15-1996	Magda et al.				
	A36	5,622,821	04-22-1997	Selvin et al.	7			
	A37 *	5,624,901	04-29-1997	Raymond et al.				
	A38 *	5,648,063	07-15-1997	Gries et al.	<del>-</del> -			
	A39	5,672,334	09-30-1997	Ranney				
	A40	5,707,605	01-13-1998	Meade et al.				
	A41 *	5,874,573	02-23-1999	Winchell et al.				
	A42 *	5,892,029	04-06-1999	Raymond et al.				
	A43 *	5,900,228	05-04-1999	Meade et al.				
	A44	5,914,095	06-22-1999	Watson				
	A45	5,955,605	09-21-1999	Axworthy et al.				
	A46 *	5,976,493	11-02-1999	Margerum et al.				
	A47	5,980,862	11-09-1999	Meade et al.				
	A48	6,054,114	04-25-2000	Lansbury et al.				
	A49 *	6,120,768	09-19-2000	Griffiths et al.				
	A50 *	6,123,921	09-26-2002	Meade et al.				
	A51 *	6,348,185 B1	02-19-2002	Piwnica-Worms				
	A52	6,409,990 B1	06-25-2002	Vera				
	A53 *	6,521,209 B1	02-18-2003	Meade et al.				
	A54 *	6,656,450 B2	12-02-2003	Hubin et al.				
	A55 *	6,673,333 B1	01-06-2004	Meade et al.				
	A56 *	6,709,646 B1	03-23-2004	Lauffer et al.				
	A57 *	6,713,045 B1	03-30-2004	Meade et al.				
	A58 *	6,713,046 B1	03-30-2004	Meade				
	A59 *	2002/0098153 A1	07-25-2002	Alten et al.				
	A60 *	2002/0197648 A1	12-26-2002	Silva et al.				
	A61 *	2003/0004236 A1	01-02-2003	Meade				
	A62 '	2003/0053954 A1	03-20-2003	Meade et al.				

			 _
Examiner	Date	1	
Signature	Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 6 if possible. Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the INSTOLLER of the property of the propert

USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Substitute for fo	rm 1449/	A/PTO	Complete if Known			
	(Modi	ified)		Application Number	10/693,252		
IN	<b>IFORMATION</b>	DISC	CLOSURE	Filing Date	October 24, 2003		
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Meade et al.		
				Art Unit	1616		
	(use as many she	ets as ne	cessary)	Examiner Name	To Be Assigned		
Sheet	3	of	6	Attorney Docket Number	A-68448-3		

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Occurnent	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A63 *	2003/0135108 A1	07-17-2003	Silva et al.	
	A64 *	2003/0198597 A1	10-23-2003	Meade et al.	
	A65				
	A66				

		FC	DREIGN PATEN	T DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	CA 2139374	07-01-1995	Meyer et al.		
	B2	CA 2182686	08-10-1995	Schering Aktiengesellschaft		
<del>-</del>	В3	CA 2197074	02-22-1996	Schering Aktiengesellschaft		
·	B4	WO 90/12050 A1	10-18-1990	Salutar, Inc.		
	B5	WO 92/19264 A1	11-12-1992	University of New Mexico		<u> </u>
	B6	WO 94/03271 A1	02-17-1994	Smith-Kline Beecham PLC		
	B7	WO 94/04485 A1	03-03-1994	Mallinckrodt Medical Inc.		
	B8	WO 95/10217 A2, A3	04-20-1995	Mallinckrodt Medical Inc.		
	B9	WO 95/19185 A1	07-20-1995	Mallinckrodt Medical Inc.		
	B10	WO 95/19347 A1	07-20-1995	Mallinckrodt Medical Inc.		
_	B11	WO 95/20353 A1	08-03-1995	Mallinckrodt Medical Inc.		
	B12	WO 95/27705 A1	10-19-1995	Bracco International		
	B13	WO 95/28966 A1	11-02-1995	Nycomed Imaging		
	B14	WO 95/31444 A1	11-23-1995	Bracco International		
	B15	WO 95/32741 A1	12-07-1995	Dibra S.P.A.		
	B16	WO 96/05167 A1	02-22-1996	Schering Aktiengesellschaft		
	B17	WO 96/23526 A2,A3	08-08-1996	Metasyn, Inc.		
	B18	WO 96/38184 A2,A3	12-05-1996	California Institute of Technology		
	B19 '	WO 97/00245 A1	01-03-1997	Regents of University of California		
	B20	WO 97/01360 A3	01-16-1997	Concat, Ltd.		

Examiner Date Considered		
	Examiner	
	Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark here if English Language Translation is attached. 

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the INSPIC) to process?

Applicant is to file (and by the INSPIC) to process?

Confidentiality coverned by 35 LIS C 122 and 37 CFB 1.14. This collection is estimated to take 2 hours to complete the complete the second of the process to complete the complete the complete the second of the process to complete the c

USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Substitute for for		VPTO	Complete if Known			
	(Modified)  INFORMATION DISCLOSURE			Application Number	10/693,252		
IN	<b>IFORMATION</b>	DISC	CLOSURE	Filing Date	October 24, 2003		
S	STATEMENT BY APPLICANT			First Named Inventor	Meade et al.		
				Art Unit	1616		
	(use as many shee	ets as ne	cessary)	Examiner Name	To Be Assigned		
Sheet	4	of	6	Attorney Docket Number	A-68448-3		

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>©</sup>				
	B21	WO 97/21431 A1	06-19-1997	California Institute of Technology						
	B22	WO 97/32862 A1	09-12-1997	Bracco S.P.A.						
	B23	WO 97/36619 A2,A3	10-09-1997	Epix Medical, Inc.						
	B24	WO 99/21592 A1	05-06-1999	California Institute of Technology						
	B25	WO 99/25389 A2	05-27-1999	Research Corporation Technologies						
	B26	WO 99/59640 A2, A3	11-25-1999	Bracco International B.V.						
	B27	WO 01/08712 A2, A3	02-08-2001	Epix Medical, Inc.						
	B28	WO 01/52906 A2, A3	07-26-2001	Epix Medical, Inc.						
	B29	WO 01/82795 A2, A3	11-08-2001	Research Corporation Technologies						
	B30 *	WO 02/056670 A2 /	07-25-2002	The General Hospital						
	B31									
	B32									

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	₽ª
	C1	AGUAYO et al., "Nuclear magnetic resonance imaging of a single cell," Nature, Letters to Nature, 07-10-1986, 322:190-191.	
	C2	ALEXANDER, "Design and Synthesis of Macrocyclic Ligands and Their Complexes of Lanthanides and Antinides," Chemical Review, 1995, 95:273-342.	
	СЗ	BORCH, R.F., et al., "The Cyanohydridoborate Anion as a Selective Reducing Agent," Journal of the American Chemical Society, 06-1971, 93(12):2897-2904.	
	C4	CHO, Z.H., et al., "Some Experiences on a 4 $\mu$ m NMR Microscopy," Book of Abstracts, Vol. 1, p.233, Society of Magnetic Resonance in Medicine, 6th Annual Meeting and Exhibition, August 17-21, 1987, New York City, NY., 08-1987, 1:233.	
	C5 ·	COHEN, S.M, et al., "Synthesis and Relaxation Properties of Mixed Gadolinium Hydroxypyridinonate MRI Contrast Agents, Inorganic Chemistry, 2000, 39:5747-5756.	
	C6	GRYNKIEWICZ, G., et al., "A New Generation of Ca2+ Indicators with Greatly Improved Fluorescence Properties," The Journal of Biological Chemistry, 1985, 260(6):3440-3450.	
	C7	HENNESSY, M.J., et al., "NMR Surface Coil Microscopy," Book of Abstracts, Vol. 2, p.461-462, Society of Magnetic Resonance in Medicine, 5th Annual Meeting and Exhibition, August 19-22, 1986, Montreal, Quebec, Canada., 08-1986, 2:461-462.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*\*</sup>Considered. Include copy of this form with next communication to applicant.

\*\*Applicant's unique citation designation number (optional).

\*\*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

\*\*Table Post Include copy of this form with next communication to applicant.

\*\*Applicant's unique citation designation number (optional).

\*\*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

\*\*Table Post Include Copy of this form with next communication to applicant is surject to the communication of the patent of the reign of the Emperor must precede the serial number of the patent document.

\*\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

\*\*Applicant is to place a check mark here if English Language Translation is a statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO			A/PTO	Complete if Known		
	(Mod	ified)		Application Number	10/693,252	
IN	<b>IFORMATION</b>	DISC	CLOSURE	Filing Date	October 24, 2003	
s	TATEMENT B	Y AF	PLICANT	First Named Inventor	Meade et al.	
				Art Unit	1616	
	(use as many she	ets as ne	cessary)	Examiner Name	To Be Assigned	
Sheet	5	of	6	Attorney Docket Number	A-68448-3	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	74		
	C8	HOULT, D.I., et al., "The Signal-to-Noise Ratio of the Nuclear Magnetic Resonance Experiment," Journal of Magnetic Resonance, 1976, 24:71-85.			
	C9	HUBIN et al., "Ultra rigid cross-bridged tetraazamacrocycles as ligands- the challenge and the solution," Chemical Communications, 1998, :1675-1676.			
	C10	HUBIN et al., "Crystallographic Characterization of Stepwise Changes in Ligand Conformations as Their Internal Topology Changes and Two Novel Cross-Bridged Tetraazamacrocyclic Copper(II) Complexes," Inorganic Chemistry, 1999, 38:4435-4446.	_		
	C11	HUBIN et al., "New Iron(II) and Manganese(II) Complexes of Two Ultra-Rigid, Cross-Bridged Tetraazamacrocycles for Catalysis and Biomimicry," Journal of the American Chemical Society, 2000, 122:2515-2522.			
_	C12 *	HUBIN et al., "Topologically Constrained Manganese(III) and Iron(III) Complexes of Two Cross-Bridged Tetraazamacrocycles," Inorganic Chemistry, 2001, 40:435-444.	_		
	C13 *	HUBIN et al., "Potentiometric Titrations and Nickel(II) Complexes of Four Topologically Constrained Tetraazamacrocycles," Supramolecular Chemistry, 2001, 13:261-276.			
	C14	JACKELS, "Enhancement Agents for Magnetic Resonance and Ultrasound Imaging. Chapter 20: Enhancement Agents for Magnetic Resonance Imaging: Fundamentals," Pharm. Med. Imag., 1990, 20(3):645-661.			
	C15	JACOBS et al., "Magnetic Resonance Microscopy of Embryonic Cell Lineages and Movements," Science, 1994, 263:681-684.			
	C16	JOHNSON, G.A., et al., "MR Microscopy at 7.0 T," Works in Progress, Society of Magnetic Resonance in Medicine, Sixth Annual Meeting and Exhibition, August 17-21, 1987, New York City, NY, 08-1987, :23.			
	C17	LI et al., "A Calcium-Sensitive Magnetic Resonance Imaging Contrast Agent," Journal of the American Chemical Society, 1999, 121:1413-1414.			
	C18	MEADE, T.J. et al., "Hydrophobic, Regiospecific Guest Binding by Transition-Metal Host Complexes Having Permanent Voids as Revealed by FT-NMR Relaxation Studies," Journal of the American Chemical Society, 1986, 108:1954-1962.			
	C19	MEYER et al., "Advances in Macrocyclic Gadolinium Complexes as Magnetic Resonance Imaging Contrast Agents," Investigative Radiology, 09-1990, 25(1):S53-S55.			
	C20	MOATS et al., "A "Smart" Magnetic Resonance Imaging Agent That Reports on Specific Enzymatic Activity," Agnew Chemical International Edition England, 04-1997, 36(7):726-728.			
	C21	MOI, M.K., et al., "The Peptide Way to Macrocyclic Bifunctional Chelating Agents: Synthesis of 2- (p-Nitrobenzyl) - 1,4,7,10-tetraazacyclododecan- N, N', N", N"- tetraacetic Acid and Study of Its Yttrium(III) Complex," Journal of the American Chemical Society, 1988, 110(18):6266-6267.			
	C22	NIJHOF, E.J., et al., "High-Resolution Proton Imaging at 4.7 Tesla," Proceedings of Soc. Magn. Reson. Med., 1987, pg. 925.			
	C23	RUNGE, V.M., et al., "Future directions in magnetic resonance contrast media," Topics in Magnetic Resonance Imaging, 1991, 3(2):85-97.			
	C24	RUSSELL, E.J., et al., "Multicenter Double-Blind Placebo-Controlled Study of Gadopentetate Dimeglumine as an MR Contrast Agent: Evaluation in Patients with Cerebral Lesions," American Journal of Recentgenology, 04-1989, 152:813-823.			

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and

the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				Complete if Known		
	(Modi	ified)		Application Number	10/693,252	
IN	<b>IFORMATION</b>	DISC	CLOSURE	Filing Date	October 24, 2003	
S	TATEMENT B	Y AF	PLICANT	First Named Inventor	Meade et al.	
				Art Unit	1616	
(use as many sheets as necessary)				Examiner Name	To Be Assigned	
Sheet	6	of	6	Attorney Docket Number	A-68448-3	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰		
	C25	SHUKLA et al., "Design of Conformationally Rigid Dimeric MRI Agents," Magnetic Resonance in Medicine, 1996, 36(6):925-931.			
	C26	SILLERUD, L.O., et al., "Proton NMR Microscopy of Intact Multicellular Tumor Spheroids," Book of Abstracts, Vol. 1, p.468, Society of Magnetic Resonance in Medicine, 6th Annual Meeting and Exhibition, August 17-21, 1987, New York City, NY, 08-1987, 1:468.			
	C27	STAUBLI et al., "The Design and Synthesis of Fluorescently Detectable Magnetic Resonance imaging Agents for Embryonic Cell Lineage Analysis," American Chemical Society: Division of Inorganic Chemistry, 209th ACS National Meeting, Anaheim, California. Abstract No. 385 (April 2-6, 1995)., 04-1995.			
	C28	TSIEN, R.Y. "New Calcium Indicators and Buffers with High Selectivity Against Magnesium and Protons: Design, Synthesis, and Properties of Prototype Structures," Biochemistry, 1980, 19(11):2396-2404.			
	C29	TWEEDLE, M.F., et al., "Considerations Involving Paramagnetic Coordination Compounds as Useful NMR Contrast Agents," Nuclear Medicine and Biology, 1988, 15(1):31-38.			
	C30	WEISMAN et al., "Cross-Bridged Cyclam. Protonation and Li+ Complexation in a Diamond-Lattice Cleft," Journal of the American Chemical Society, 1990, 112:8604-8605.			
	C31	WEISMAN et al., "Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands," Chemical Communications, 1996, pp. 947-948.			
	C32	WONG et al., "Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) Complexes," Journal of the American Chemical Society, 2000, 122:10561-10572.			
	C33				
	C34				
	C35				
	C36				
	C37				
	C38				
	C39				

Examiner	Date Considered
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

It wou need assistance in completion this form call 1.800-PTO-2199 (1.800-786-2199) and selection online 2